Patents by Inventor Yves Girerd-Chambaz
Yves Girerd-Chambaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131142Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: ApplicationFiled: January 4, 2024Publication date: April 25, 2024Applicants: CureVac SE, Sanofi PasteurInventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
-
Patent number: 11931406Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: GrantFiled: December 12, 2018Date of Patent: March 19, 2024Assignees: CureVac SE, Sanofi PasteurInventors: Patrick Baumhof, Wolfgang Grosse, Edith Jasny, Thomas Kramps, Daniel Voss, Julia Dannenmaier, Valérie Lecouturier, Yves Girerd-Chambaz
-
Publication number: 20240024453Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.Type: ApplicationFiled: June 21, 2023Publication date: January 25, 2024Applicants: CureVac SE, Sanofi PasteurInventors: Benjamin PETSCH, Edith JASNY, Yves GIRERD-CHAMBAZ
-
Patent number: 11723967Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.Type: GrantFiled: February 17, 2017Date of Patent: August 15, 2023Assignees: CureVac SE, Sanofi PasteurInventors: Benjamin Petsch, Edith Jasny, Yves Girerd-Chambaz
-
Patent number: 11690903Abstract: The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue naïve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4.Type: GrantFiled: October 5, 2018Date of Patent: July 4, 2023Assignee: SANOFI PASTEURInventors: Diana Coronel, Betzana Zambrano, Fernando Noriega, Tram Anh Wartel, Yves Girerd-Chambaz
-
Patent number: 11471521Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.Type: GrantFiled: April 2, 2019Date of Patent: October 18, 2022Assignee: Sanofi PasteurInventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
-
Patent number: 11452772Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.Type: GrantFiled: November 5, 2021Date of Patent: September 27, 2022Assignee: Sanofi PasteurInventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
-
Publication number: 20220047692Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.Type: ApplicationFiled: November 5, 2021Publication date: February 17, 2022Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
-
Publication number: 20210154289Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.Type: ApplicationFiled: April 2, 2019Publication date: May 27, 2021Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
-
Patent number: 10946087Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.Type: GrantFiled: September 2, 2015Date of Patent: March 16, 2021Assignee: SANOFI PASTEURInventors: Nadia Tornieporth, Alain Bouckenooghe, Fernando Noriega, Melanie Saville, Nicholas Jackson, Yves Girerd-Chambaz
-
Publication number: 20210069315Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: ApplicationFiled: December 12, 2018Publication date: March 11, 2021Inventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
-
Patent number: 9937252Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.Type: GrantFiled: February 6, 2014Date of Patent: April 10, 2018Inventors: Gary McLean, Walton Ross, Sebastian Johnston, Nathan Wylie Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
-
Publication number: 20160095916Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.Type: ApplicationFiled: February 6, 2014Publication date: April 7, 2016Applicants: SANOFI PASTEUR, IMPERIAL INNOVATIONS LIMITEDInventors: Gary McLean, Walton Ross, Sebastian Johnson, Nathan Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
-
Publication number: 20150265695Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.Type: ApplicationFiled: July 24, 2013Publication date: September 24, 2015Inventors: Jiansheng Yao, Yves Girerd-Chambaz, Isabelle Legastelois, Nathalie Mantel, Véronique Barban, Jean Lang, Bruno Guy